TICKERNOMICS Sign up
Last Update: 2024-03-28 02:11:21
AGIOS PHARMACEUTICALS INC. ( AGIO ) https://www.agios.com
29.06USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
31.15%
AGIO
28.87%
SPY
32.74%
-41.46%
AGIO
SPY
92.93%
-56.91%
AGIO
SPY
224.41%
-21.50%
AGIO
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
1671.64
1160.48
0.53
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-22.49
69.56
2.06
-18.79
0.00
-3.06
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-1363.66
91.44
-1397.16
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
7.7016
-82.05
-39.47
0.92
Other Earnings and Cash Flow Stats:
AGIOS PHARMACEUTICALS INC. ( AGIO ) Net Income TTM ($MM) is -62.93
AGIOS PHARMACEUTICALS INC. ( AGIO ) Operating Income TTM ($MM) is -381.77
AGIOS PHARMACEUTICALS INC. ( AGIO ) Owners' Earnings Annual ($MM) is -283.04
AGIOS PHARMACEUTICALS INC. ( AGIO ) Current Price to Owners' Earnings ratio is -5.74
AGIOS PHARMACEUTICALS INC. ( AGIO ) EBITDA TTM ($MM) is -378.85
AGIOS PHARMACEUTICALS INC. ( AGIO ) EBITDA Margin is -1397.16%
Capital Allocation:
AGIOS PHARMACEUTICALS INC. ( AGIO ) has paid 0.00 dividends per share and bought back -1.155643 million shares in the past 12 months
AGIOS PHARMACEUTICALS INC. ( AGIO ) has reduced its debt by 13.663 million USD in the last 12 months
Capital Structure:
AGIOS PHARMACEUTICALS INC. ( AGIO ) Interest-bearing Debt ($MM) as of last quarter is 72
AGIOS PHARMACEUTICALS INC. ( AGIO ) Annual Working Capital Investments ($MM) are -19
AGIOS PHARMACEUTICALS INC. ( AGIO ) Book Value ($MM) as of last quarter is 811
AGIOS PHARMACEUTICALS INC. ( AGIO ) Debt/Capital as of last quarter is 8%
Other Balance Sheet Stats:
AGIOS PHARMACEUTICALS INC. ( AGIO ) has 88 million in cash on hand as of last quarter
AGIOS PHARMACEUTICALS INC. ( AGIO ) has 67 million of liabilities due within 12 months, and long term debt 0 as of last quarter
AGIOS PHARMACEUTICALS INC. ( AGIO ) has 55 common shares outstanding as of last quarter
AGIOS PHARMACEUTICALS INC. ( AGIO ) has 0 million USD of preferred stock value
Academic Scores:
AGIOS PHARMACEUTICALS INC. ( AGIO ) Altman Z-Score is 6.37 as of last quarter
AGIOS PHARMACEUTICALS INC. ( AGIO ) Piotroski Score is 4.00 as of last quarter
Corporate Governance:
AGIOS PHARMACEUTICALS INC. ( AGIO ) largest shareholder is Farallon Capital Management, L.L.C. owning 4167602 shares at 121.11 ($MM) value
Brian Goff(an insider) Sold 4156 shares of AGIOS PHARMACEUTICALS INC. ( AGIO ) for the amount of $135360.92 on 2024-03-05
1.41% of AGIOS PHARMACEUTICALS INC. ( AGIO ) is held by insiders, and 105.91% is held by institutions
AGIOS PHARMACEUTICALS INC. ( AGIO ) went public on 2013-07-24
Other AGIOS PHARMACEUTICALS INC. ( AGIO ) financial metrics:
FCF:-280.57
Unlevered Free Cash Flow:-276.41
EPS:-6.53
Operating Margin:-1363.66
Gross Profit Margin:91.44
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-45.04
Beta:0.92
Buffet's Owners Earnings:-283.04
Price to Owner's Earnings:-5.74
About AGIOS PHARMACEUTICALS INC. ( AGIO ) :
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism. The company develops PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias; and AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.